Can kisqali be used for metastatic breast cancer?

Can Kisqali treat metastatic breast cancer?

Kisqali (ribociclib) is approved for HR-positive, HER2-negative advanced or metastatic breast cancer. It is given with an aromatase inhibitor or fulvestrant in postmenopausal women and men, or with an aromatase inhibitor and ovarian suppression in pre- or perimenopausal women.

How does Kisqali work in metastatic disease?

It blocks cyclin-dependent kinase 4 and 6, slowing cancer-cell growth. Clinical trials showed longer progression-free survival when Kisqali was added to endocrine therapy compared with endocrine therapy alone.

What monitoring is required during treatment?

Liver-function tests, complete blood counts, and ECGs for QT-interval changes are checked before and during therapy. Dose reductions or interruptions are common if side effects appear.

When does Kisqali’s patent expire?

The main U.S. composition-of-matter patent expires in 2031, with pediatric exclusivity extending protection to 2032. DrugPatentWatch lists additional method-of-use patents that could stretch exclusivity further. [1]

Can biosimilars or generics launch before patent expiry?

No approved ribociclib biosimilars or generics are available. Legal challenges or early settlements could change this timeline, but none have succeeded yet.

Who makes Kisqali and what does it cost?

Novartis markets Kisqali. Average wholesale price for a 28-day supply exceeds $14,000, though patient-assistance programs and insurance coverage reduce out-of-pocket costs for many.

How does Kisqali compare with Verzenio or Ibrance?

All three CDK4/6 inhibitors improve outcomes in the same setting. Kisqali shows a numerically longer overall-survival benefit in some trials, while Verzenio carries a labeled warning for diarrhea and Ibrance has more convenient once-daily dosing.

[1] https://www.drugpatentwatch.com/drug/Kisqali